Plasma and CSF levels of NfL, a cytoskeletal protein specifically expressed in neurons, are used as a state-of-the-art biomarker for neuroaxonal damage and is associated with encephalomyelitis and cognitive impairment. This evidence concerns the gene NEFL and encephalomyelitis.